- U.S. Data Highlights Oral Xeloda versus Standard Infusional Chemotherapy
in Gastroesophageal and Colorectal Cancers -
NUTLEY, N.J., Jan. 24 /PRNewswire/ -- Roche announced today that a total of 33 abstracts involving its oral chemotherapy Xeloda(R) have been accepted for presentation at the 2008 Gastrointestinal Cancers Symposium in Orlando, Fla., from Jan. 25 to 27.
Five poster presentations based on U.S. data offer additional knowledge
about Xeloda. Two of these U.S. abstracts compare the safety profile and
usage patterns of therapy with oral Xeloda to that of intravenous
fluorouracil (5-FU) therapy in gastroesophageal cancer. A second pair of
U.S. abstracts evaluates the usage patterns and cost of Xeloda-based
regimens against those of 5-FU-based regimens in colon and rectal cancer.
The fifth U.S. abstract highlights preclinical efficacy and tolerability
results of a novel Xeloda regimen (7/7, or 7 days on, 7 days off) using
higher daily doses for the treatment of colorectal cancer.
-- Jan. 25, noon to 1 p.m., [Poster No. 72], A claims database analysis of
capecitabine treatment patterns in patients with gastroesophageal
cancer (GEC) (Presenter: Wasif Saif)
-- Jan. 25, noon to 1 p.m., [Poster No. 71], Capecitabine in patients with
gastroesophageal cancer (GEC): A claims database analysis of adverse
events (AEs) (Presenter: Wasif Saif)
-- Jan. 26, 5:30 to 6:30 p.m., [Poster No. 364], A claims database cost-
comparison analysis of capecitabine in the treatment of patients with
colon or rectal cancer (CRC) (Presenter: Edward Chu)
-- Jan. 27, 7 to 8 a.m., [Poster No. 465], Capecitabine use in patients
with colon and rectal cancer (CRC): A claims database analysis of
treatment (Presenter: Edward Chu)
-- Jan. 27, 7 to 8 a.m., [Poster No. A29], In vivo activity of traditional
vs. novel regimens of capecitabine (C) alon
Copyright©2008 PR Newswire.
All rights reserved